Shattuck Labs, Inc.

General Information
Business:

We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the immune system. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. 

Our lead wholly owned product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. We are currently conducting a Phase 1 clinical trial evaluating SL-172154 in patients with ovarian cancer, and we expect to announce initial data from the dose-escalation portion of this trial in the second half of 2021. Our second product candidate, SL-279252, which is being developed in collaboration with Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. We are evaluating SL-279252 in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma, and we expect to announce data from the dose-escalation portion of this trial in the second half of 2021

Industry: Pharmaceuticals
Employees: 45
Founded: 2016
Contact Information
Address 1018 W. 11th Street, Suite 100 Austin, TX 78703
Phone Number (919) 864-2700
Web Address https://www.shattucklabs.com/
View Prospectus: Shattuck Labs, Inc.
Financial Information
Market Cap $571.2mil
Revenues $10.8 mil (last 12 months)
Net Income $-27.5 mil (last 12 months)
IPO Profile
Symbol STTK
Exchange NASDAQ
Shares (millions): 11.9
Price range $17.00 - $17.00
Est. $ Volume $202.3 mil
Manager / Joint Managers Citigroup/ Cowen/ Evercore ISI
CO-Managers Needham & Co.
Expected To Trade: 10/9/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change